List of Excipients in Branded Drug ARIMIDEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	ARIMIDEX	anastrozole	54868-5000	HYPROMELLOSES
Physicians Total Care Inc	ARIMIDEX	anastrozole	54868-5000	LACTOSE
Physicians Total Care Inc	ARIMIDEX	anastrozole	54868-5000	MAGNESIUM STEARATE
Physicians Total Care Inc	ARIMIDEX	anastrozole	54868-5000	POLYETHYLENE GLYCOL

Arimidex Excipient Strategy and Commercial Opportunities for Anastrozole Tablets

Last updated: September 9, 2026

Arimidex is the branded formulation of anastrozole, a nonsteroidal aromatase inhibitor approved by the FDA for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer and for advanced breast cancer. Its commercial patent exclusivity has expired, and the active ingredient is available through multiple generic manufacturers. The principal excipient opportunity is therefore not protection of the original molecule, but cost-efficient, differentiated, and patient-tolerable formulations for anastrozole 1 mg tablets.

The reference formulation uses conventional, widely available excipients. Its low formulation complexity reduces technical barriers to generic entry but creates limited room for premium pricing unless a competitor improves swallowability, excipient tolerability, packaging, adherence, or distribution economics.

What excipients are used in Arimidex tablets?

The U.S. Arimidex tablet contains anastrozole at a strength of 1 mg. The labeled inactive ingredients are lactose monohydrate, povidone, sodium starch glycolate, magnesium stearate, hypromellose, macrogol 300, and titanium dioxide. These materials are used in the tablet core and film coating for binding, disintegration, lubrication, coating, and appearance control (AstraZeneca Pharmaceuticals LP, 2021).

Component	Function in the formulation	Commercial implication
Lactose monohydrate	Diluent and tablet bulk agent	Low cost; creates a lactose-intolerance and dairy-derived excipient consideration
Povidone	Binder and granulation aid	Supports tablet hardness and processability
Sodium starch glycolate	Superdisintegrant	Promotes rapid tablet breakup
Magnesium stearate	Lubricant	Controls ejection and reduces manufacturing friction
Hypromellose	Film-coating polymer	Provides coating integrity and visual uniformity
Macrogol 300	Plasticizer and coating aid	Improves coating flexibility
Titanium dioxide	Opacifier and pigment	Supports appearance and light protection

The formulation is a conventional immediate-release film-coated tablet. No modified-release matrix, osmotic delivery system, lipid vehicle, or complex enabling technology is required.

What is the commercial role of each Arimidex excipient?

Lactose-free formulation opportunity

Lactose is the most commercially relevant excipient in the reference product. A generic manufacturer can replace lactose with mannitol, microcrystalline cellulose, dibasic calcium phosphate, or another suitable diluent, subject to formulation development and ANDA requirements.

A lactose-free product could be positioned for:

• Patients who avoid lactose or dairy-derived materials.
• Hospital formularies with excipient-standardization policies.
• Markets that prefer plant-derived or synthetic excipients.
• Contract manufacturing programs seeking broader excipient flexibility.
• Private-label products with differentiated labeling.

The commercial value of a lactose-free claim is likely to be higher than any technical advantage because the reference tablet is otherwise simple and mature.

Direct-compression strategy

A direct-compression formulation could reduce processing steps compared with wet granulation. Microcrystalline cellulose, spray-dried lactose, mannitol, or co-processed excipients may provide adequate flow, compactability, and disintegration.

The key development risks are low-dose content uniformity and over-lubrication. Anastrozole represents only 1 mg of a tablet, so blend uniformity is more important than bulk tablet size. Magnesium stearate concentration and mixing time can affect dissolution and tablet strength.

A direct-compression process may provide:

• Lower equipment and energy use.
• Shorter manufacturing cycle time.
• Fewer in-process operations.
• Easier technology transfer.
• Lower cost for high-volume generic supply.

The formulation must still demonstrate acceptable dissolution, assay uniformity, impurities, stability, and bioequivalence.

Co-processed excipients

Co-processed excipients can improve flow and compaction in a low-dose tablet. They may be useful where a manufacturer wants to eliminate wet granulation while retaining consistent tablet hardness and rapid disintegration.

The principal limitation is cost. A premium co-processed excipient may reduce manufacturing complexity but increase material cost and supplier dependence. For an established generic product with several suppliers, the economic case depends on throughput, yield, labor, and quality-control savings.

Coating-system alternatives

The reference product uses hypromellose, macrogol, and titanium dioxide. A generic manufacturer can use an alternative film-coating system, including a pre-mixed hypromellose coating or a polyvinyl alcohol-based system.

Potential commercial objectives include:

• Titanium dioxide-free coating.
• Lower coating weight gain.
• Faster coating cycles.
• Improved color matching.
• Reduced risk of coating defects.
• Simplified global sourcing.

Coating changes are unlikely to produce strong exclusivity by themselves. Their value lies in manufacturing efficiency, supply resilience, and labeling differentiation.

What formulations are protected by Arimidex patents?

The original Arimidex formulation and anastrozole product were protected primarily through historical composition-of-matter and product-related patent rights. The principal U.S. anastrozole patent commonly associated with Arimidex is U.S. Patent No. 4,935,970, assigned to Imperial Chemical Industries, the predecessor organization associated with AstraZeneca’s oncology portfolio. The patent expired in 2010, subject to applicable patent-term calculations and regulatory extensions (U.S. Patent and Trademark Office, 1990).

The expired patent estate does not create a current formulation moat for conventional anastrozole tablets. A manufacturer using different excipient ratios or a different coating system generally does not need a license to the original reference formulation solely because the product contains the same common excipients.

A new formulation could receive patent protection only if it contains a patentable technical feature, such as:

• A novel solid-state form.
• A demonstrated stability improvement.
• A specific particle-size distribution with an unexpected performance benefit.
• A novel taste-masking system.
• A technically superior lactose-free composition.
• A new dosage form or delivery route.
• A combination with a separately protected active ingredient.
• A manufacturing process that produces a non-obvious product attribute.

A simple substitution of lactose with mannitol or microcrystalline cellulose would usually face a weak obviousness position unless supported by unexpected results.

When did Arimidex lose exclusivity?

Arimidex lost small-molecule exclusivity after the expiration of the primary anastrozole patent in 2010. The FDA approved Arimidex in December 1995. Generic anastrozole products entered the U.S. market after the end of the principal patent barrier, and the product is now a mature generic market (U.S. Food and Drug Administration, 1995; U.S. Food and Drug Administration, n.d.-a).

Event	Date or status
FDA approval of Arimidex	December 1995
Primary U.S. anastrozole patent	U.S. Patent No. 4,935,970
Primary patent expiration	2010
Generic anastrozole availability	Began after loss of primary patent protection
Current regulatory category	Generic immediate-release tablet
Biosimilar pathway	Not applicable

Arimidex does not have biologic exclusivity. Anastrozole is a chemically synthesized small molecule, so biosimilar litigation and the Biologics Price Competition and Innovation Act pathway do not apply.

What is the Orange Book status of Arimidex?

The Orange Book historically listed Arimidex as a prescription drug product with patent information associated with the original anastrozole rights. The commercial relevance of those listings has diminished because the principal patent protection expired and generic anastrozole products have been approved.

The Orange Book remains relevant for determining:

• Approved reference listed drug status.
• Patent listings associated with a product.
• Generic applicant certifications.
• Therapeutic-equivalence evaluations.
• Approval status of anastrozole tablets.

Current applicants should distinguish between historical patent records and live, enforceable patent barriers. A product-specific Orange Book review should be conducted before filing or investing in a new anastrozole product because listings and regulatory records can change (U.S. Food and Drug Administration, n.d.-b).

Are Paragraph IV challenges still relevant for Arimidex?

Paragraph IV challenges were commercially relevant before expiration of the primary Arimidex patent. An ANDA applicant could certify that a listed patent was invalid, unenforceable, or would not be infringed. That certification could trigger patent litigation and a possible 30-month stay under the Hatch-Waxman framework.

For a new conventional anastrozole tablet today, the main risk is unlikely to be an original Arimidex patent. The more relevant issues are:

• Whether a later-listed patent exists.
• Whether a formulation or method-of-use patent is listed.
• Whether the applicant relies on the same labeling.
• Whether the product creates a new patentable formulation feature.
• Whether state substitution rules affect market access.

A Paragraph IV strategy has limited commercial value when the main product patents have expired. The filing advantage comes from efficient development, reliable supply, and abbreviated regulatory review rather than early patent litigation.

What FDA regulatory pathway applies to anastrozole tablets?

A conventional generic anastrozole 1 mg tablet would generally be developed through an ANDA referencing the Arimidex reference listed drug. The applicant must establish pharmaceutical equivalence, bioequivalence, manufacturing quality, and labeling conformity.

Key technical requirements include:

• Same active ingredient and strength.
• Same dosage form and route of administration.
• Comparable performance and dissolution.
• Bioequivalence under FDA requirements.
• Compliance with current good manufacturing practices.
• Adequate stability data.
• Control of impurities and degradation products.
• Suitable content-uniformity controls for the 1 mg dose.

A 505(b)(2) application could be relevant to a materially different formulation, dosage form, route, or indication. It would be less efficient for a conventional tablet that can be approved through the ANDA pathway.

What method-of-use patents affect anastrozole?

Arimidex is indicated for adjuvant treatment of early breast cancer and treatment of advanced breast cancer in postmenopausal women. Method-of-use patents can be relevant when a generic applicant seeks an indication or dosing regimen that remains protected.

For a standard generic product, the principal commercial strategy is usually a carve-out of protected labeling, where permitted. The manufacturer must ensure that the proposed labeling does not encourage an infringing use. Regulatory approval of the tablet does not automatically eliminate method-of-use patent risk.

Potential method-of-use claim areas include:

• Specific treatment settings.
• Sequencing after tamoxifen.
• Duration of adjuvant therapy.
• Patient-selection criteria.
• Combination treatment.
• Biomarker-defined populations.

The business value of a method-of-use patent depends on whether the patented use represents a material share of prescriptions and whether physicians can prescribe the generic for unprotected uses without inducing infringement.

How strong is the Arimidex patent estate?

The original Arimidex estate is weak as a current barrier to conventional generic entry because the core small-molecule patent has expired and the formulation uses standard excipients.

Patent-estate factor	Assessment
Composition-of-matter protection	Expired
Conventional tablet formulation protection	Limited current barrier
Biologic exclusivity	Not applicable
Biosimilar defense	Not applicable
Manufacturing complexity	Low to moderate
Excipient availability	High
Generic substitution risk	High
Potential for differentiated reformulation	Moderate
Potential for premium pricing	Low without clinical or adherence benefit

The stronger competitive advantages are operational. They include API sourcing, validated analytical methods, low-cost tableting, high manufacturing yield, reliable packaging, and broad wholesaler access.

Which companies are challenging or competing with Arimidex?

Arimidex competes with generic anastrozole manufacturers rather than with biosimilar developers. U.S. generic supply has historically included large generic companies such as Teva, Sandoz, Mylan, Dr. Reddy’s Laboratories, and Sun Pharmaceutical Industries, although supplier participation varies by time, market, and product availability.

The relevant competitive set includes:

• Authorized generic or brand-linked supply.
• ANDA-approved anastrozole tablets.
• Other aromatase inhibitors such as letrozole and exemestane.
• Tamoxifen in selected treatment settings.
• Hospital and specialty-pharmacy private-label products.

Competition is driven by price, wholesaler contracts, supply reliability, tablet appearance, bottle size, and formulary status. Excipient differentiation has a secondary role unless a buyer specifically requires lactose-free, titanium dioxide-free, or otherwise modified products.

How does Arimidex compare with letrozole and exemestane?

Attribute	Anastrozole	Letrozole	Exemestane
Brand	Arimidex	Femara	Aromasin
Drug class	Nonsteroidal aromatase inhibitor	Nonsteroidal aromatase inhibitor	Steroidal aromatase inactivator
Typical oral strength	1 mg	2.5 mg	25 mg
Generic status	Mature generic	Mature generic	Mature generic
Biosimilar relevance	None	None	None
Formulation complexity	Low	Low	Low
Excipient differentiation opportunity	Moderate	Moderate	Moderate
Main commercial pressure	Generic price competition	Generic price competition	Generic price competition

Anastrozole has no clear excipient-based advantage over the competing aromatase inhibitors. A supplier can gain share through a lower-cost process, better fill rates, easier-to-swallow tablets, or differentiated excipient labeling.

What commercial opportunities exist for Arimidex excipients?

Hospital and institutional products

Hospitals may value products with consistent supply, simple excipient declarations, and packaging that reduces medication errors. A manufacturer could offer unit-dose blistering, calendar packaging, or barcoded cartons. These changes do not necessarily create patent protection but can improve procurement positioning.

Patient-tolerability positioning

Potential product concepts include:

• Lactose-free anastrozole tablets.
• Titanium dioxide-free film coating.
• Smaller tablets with equivalent dose delivery.
• Low-dust or low-static manufacturing.
• Packaging designed for older patients.

Any patient-facing claim must be supported by the product’s actual composition and applicable regulatory requirements.

Global-market formulation platform

A common excipient platform can support multiple jurisdictions if it meets regional requirements for excipient labeling, colorants, allergen declarations, and pharmaceutical-grade specifications. The main geographic issues are not patent barriers but regulatory and supply-chain differences.

A platform using globally accepted excipients may reduce:

• Country-specific reformulation.
• Separate stability programs.
• Supplier qualification work.
• Artwork and labeling changes.
• Manufacturing-site complexity.

Contract development and manufacturing

Anastrozole is suitable for contract manufacturing because it is a low-dose, high-volume, immediate-release product with a mature process. Service providers can compete on:

• Blend uniformity.
• Continuous manufacturing.
• High-speed compression.
• Film-coating efficiency.
• Packaging automation.
• Analytical method transfer.
• Multi-country regulatory support.

The most defensible commercial advantage is process reliability rather than an exclusive excipient composition.

What generic launch scenarios exist for anastrozole?

Scenario	Product concept	Commercial potential	Main risk
Low-cost standard generic	Reference-like tablet	High volume, low margin	Price erosion
Lactose-free generic	Alternative diluent	Moderate differentiation	Limited willingness to pay
Titanium dioxide-free product	Alternative coating	Moderate institutional appeal	No strong clinical advantage
Smaller tablet	Higher compaction or optimized blend	Moderate adherence value	Dissolution and manufacturability
Unit-dose product	Blister or calendar pack	Moderate institutional value	Packaging cost
505(b)(2) reformulation	New dosage form or delivery system	Potentially higher margin	Clinical and regulatory burden
Combination product	Anastrozole with another active	Potentially differentiated	Development and patent complexity

The most practical near-term strategy is a lactose-free or simplified, cost-optimized generic supported by high manufacturing reliability. A premium reformulation requires evidence of a meaningful adherence, tolerability, or administration benefit.

What revenue exposure does Arimidex create?

Brand Arimidex revenue exposure is limited because the market is mature and genericized. Current commercial exposure is concentrated in generic anastrozole volume, contract supply, and institutional procurement rather than branded pricing.

For excipient suppliers, the opportunity is an aggregate platform across aromatase inhibitors and other low-dose oncology tablets. Individual Arimidex-derived excipient revenue is unlikely to justify a dedicated proprietary excipient unless the same technology applies across multiple products.

The strongest economic levers are:

1. Lower cost per tablet.
2. Reduced manufacturing cycle time.
3. Fewer rejected batches.
4. Improved supply continuity.
5. Reduced packaging and distribution cost.
6. Qualification across multiple products and markets.

Key Takeaways

• Arimidex is anastrozole 1 mg, an immediate-release film-coated tablet.
• The reference formulation uses lactose monohydrate, povidone, sodium starch glycolate, magnesium stearate, hypromellose, macrogol 300, and titanium dioxide.
• The principal U.S. patent protection expired in 2010.
• Anastrozole is a small molecule, so biosimilar risk is not applicable.
• Conventional generic entry faces low formulation and manufacturing barriers.
• Lactose-free, titanium dioxide-free, smaller-tablet, and unit-dose products offer the clearest excipient-related opportunities.
• A simple excipient substitution is unlikely to support strong patent protection.
• The most valuable competitive advantages are manufacturing efficiency, supply reliability, packaging, and procurement access.
• A conventional product generally fits the ANDA pathway; a materially different formulation may require a 505(b)(2) strategy.
• Current Orange Book and FDA records remain necessary for product-specific patent and approval assessment.

FAQs About Arimidex Excipients and Commercial Strategy

Does Arimidex contain lactose?

Yes. The U.S. Arimidex tablet label identifies lactose monohydrate as an inactive ingredient. A generic manufacturer can develop a lactose-free anastrozole formulation using a different diluent, subject to FDA quality and bioequivalence requirements.

Can anastrozole be formulated without titanium dioxide?

Yes. Titanium dioxide is used as a coating pigment and opacifier, not as an essential component of anastrozole delivery. A manufacturer can evaluate alternative coating systems, although the change must meet product-quality, appearance, stability, and regulatory requirements.

Is anastrozole suitable for continuous manufacturing?

Potentially. Its low-dose immediate-release tablet profile is compatible with continuous blending and compression development. The critical controls are content uniformity, blend segregation, lubrication, dissolution, and process analytical technology.

Can a lactose-free anastrozole tablet receive new patent protection?

Possibly, but ordinary lactose substitution is unlikely to provide strong patent protection by itself. A credible patent position would require a novel composition or process with non-obvious technical advantages and supporting data.

Is a new Arimidex formulation eligible for pediatric exclusivity?

Pediatric exclusivity is a regulatory incentive, not an automatic property of a new excipient formulation. Its availability would depend on an FDA-issued written request and completion of qualifying pediatric studies. No pediatric exclusivity should be assumed for a conventional reformulation.

References

1. AstraZeneca Pharmaceuticals LP. (2021). Arimidex (anastrozole) tablets: U.S. prescribing information. Wilmington, DE: Author.

2. U.S. Food and Drug Administration. (1995). Arimidex approval letter and prescribing information. Silver Spring, MD: U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (n.d.-a). Drugs@FDA: Arimidex (anastrozole) product information. Silver Spring, MD: U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. Silver Spring, MD: U.S. Department of Health and Human Services.

5. U.S. Patent and Trademark Office. (1990). U.S. Patent No. 4,935,970: Triazole derivatives. Washington, DC: U.S. Department of Commerce.